Bendamustine Hydrochloride Injection, Solution — FDA Drug Shortage

To Be Discontinued — Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)

The FDA lists a drug shortage record for Bendamustine Hydrochloride Injection, Solution (injection) from Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.) with status To Be Discontinued. The shortage was first posted on 07/23/2026.

Shortage Details

Status
To Be Discontinued
Company
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)
Package NDC
63459-390-08
Dosage Form
Injection
Presentation
Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)
Initial Posting
07/23/2026
Revised Date